According to the FDA GnRH agonists may increase in the risk of diabetes and various cardiovascular diseases. Although the increased risk may be small, it is statistically significant. At this time the FDA is not making any conclusions as to the safety of these drugs. It also recommends that patients should not stop treatment with GnRH agonist unless instructed by their physician.
For more information go to: GnRH Agonists: Safety Review of Drug Class Used to Treat Prostate Cancer
GnRH Agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard, Synarel), Used to Treat Prostate Cancer, May Increase Risk of Diabetes and Cardiovascular Disease (5.3.10)
May 3, 2010
last few days our group held a similar discussion about this topic and you point out something we have not covered yet, appreciate that.
I see this knowledge very useful. Thanks for the important data and insights you have so offered in this article. Keep writing!